Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kenvue Inc. Common Stock (KVUE) vs Merck & Co., Inc. (MRK) Price & Performance

Kenvue Inc. Common StockTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Kenvue Inc. Common Stock vs Merck & Co., Inc. — how do they compare? Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 10.3× Kenvue Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays the higher dividend (4.74%). Which is the better fit depends on your goals.

KVUEMRK
Market Cap
$34.06B$351.28B
Volume
23,267,2287,969,665
Sector
Consumer StaplesHealth
52-Week High
$19.83$156.43
52-Week Low
$14.11$82.49
Enterprise Value
$41.56B$398.04B
Dividend Yield
4.74%2.39%
Typical Hold Time
—98 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kenvue Inc. Common Stock

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.

The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KVUE

No sentiment data available yet.

MRK
60% Buy40% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →